Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Lymphoid 1

Conditions

Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1NSCLC 1Lung Neoplasms 1

Interventions

Carboplatin 347pembrolizumab 325Pemetrexed 247Cisplatin 220Paclitaxel 148Nivolumab 139durvalumab 134Docetaxel 112osimertinib 110atezolizumab 106Specimen Handling 91Drug Therapy 87Radiotherapy 86Magnetic Resonance Spectroscopy 77Etoposide 77Radiosurgery 72Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Taxes 34Cetuximab 34Biopsy 33Standard of Care 32Platinum 32Injections 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
sugemalimab × Thoracic × 1 year × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Sichuan University

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Peking Union Medical College

Phase NA Recruiting
150 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡